Vanguard Group Inc. Reduces Position in Insmed, Inc. $INSM

Vanguard Group Inc. trimmed its position in Insmed, Inc. (NASDAQ:INSM) by 3.4% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 17,644,492 shares of the biopharmaceutical company’s stock after selling 623,630 shares during the quarter. Vanguard Group Inc. owned 9.30% of Insmed worth $1,775,742,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in INSM. ANB Bank purchased a new position in shares of Insmed in the second quarter valued at about $206,000. Kingsview Wealth Management LLC bought a new stake in shares of Insmed in the second quarter worth about $228,000. Cetera Investment Advisers increased its holdings in Insmed by 52.1% during the 2nd quarter. Cetera Investment Advisers now owns 31,462 shares of the biopharmaceutical company’s stock valued at $3,166,000 after purchasing an additional 10,783 shares during the period. Creative Planning raised its position in Insmed by 0.6% during the 2nd quarter. Creative Planning now owns 72,176 shares of the biopharmaceutical company’s stock valued at $7,264,000 after purchasing an additional 432 shares during the last quarter. Finally, Fiera Capital Corp lifted its holdings in Insmed by 29.1% in the 2nd quarter. Fiera Capital Corp now owns 748,037 shares of the biopharmaceutical company’s stock worth $75,282,000 after buying an additional 168,800 shares during the period.

Insiders Place Their Bets

In other news, Director Leo Lee sold 75,000 shares of Insmed stock in a transaction on Monday, November 17th. The shares were sold at an average price of $195.90, for a total transaction of $14,692,500.00. Following the transaction, the director owned 54,677 shares in the company, valued at $10,711,224.30. This trade represents a 57.84% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Melvin Md Sharoky sold 10,000 shares of the company’s stock in a transaction on Friday, September 12th. The stock was sold at an average price of $145.39, for a total value of $1,453,900.00. Following the completion of the sale, the director owned 262,675 shares of the company’s stock, valued at $38,190,318.25. This trade represents a 3.67% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 252,922 shares of company stock valued at $43,533,383. 3.00% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on INSM. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Insmed in a research note on Wednesday, October 8th. Cowen reaffirmed a “buy” rating on shares of Insmed in a research report on Thursday. Cantor Fitzgerald started coverage on shares of Insmed in a research report on Tuesday, October 28th. They set an “overweight” rating and a $192.00 price target on the stock. TD Cowen lifted their price objective on Insmed from $223.00 to $231.00 and gave the company a “buy” rating in a research report on Thursday. Finally, JPMorgan Chase & Co. raised their target price on Insmed from $111.00 to $135.00 and gave the company an “overweight” rating in a research note on Wednesday, August 20th. Nineteen equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Insmed presently has an average rating of “Moderate Buy” and a consensus target price of $175.53.

Insmed Stock Performance

Insmed stock opened at $198.76 on Friday. Insmed, Inc. has a twelve month low of $60.40 and a twelve month high of $208.00. The company has a quick ratio of 6.33, a current ratio of 6.68 and a debt-to-equity ratio of 0.45. The company has a market capitalization of $42.39 billion, a P/E ratio of -34.81 and a beta of 1.05. The stock’s 50 day moving average is $167.74 and its 200 day moving average is $124.79.

Insmed (NASDAQ:INSM) last announced its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported ($1.75) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.40). Insmed had a negative return on equity of 195.37% and a negative net margin of 259.82%.The firm had revenue of $142.34 million during the quarter, compared to analysts’ expectations of $114.33 million. During the same quarter in the previous year, the firm earned ($1.27) earnings per share. Insmed’s revenue was up 52.4% on a year-over-year basis. Insmed has set its FY 2025 guidance at EPS. On average, equities research analysts predict that Insmed, Inc. will post -4.56 earnings per share for the current fiscal year.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.